Olaris was an inaugural awardee of MLSC’s MassNextGen Initiative
Olaris, a precision medicine company that is fundamentally changing how diseases are diagnosed and treated, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). With this funding Olaris will work to identify biomarkers that can detect Parkinson’s disease (PD) at its earliest onset, a critical step to improving PD patient outcomes.
Olaris was an inaugural awardee of the MLSC’s Massachusetts Next Generation Initiative (MassNextGen), which aims to ensure greater gender parity in the next generation of life science entrepreneurs.
